Immunotherapy plus targeted drug for advanced melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have advanced melanoma (stage IIIC, IIID, or IV) that cannot be surgically removed; uveal melanoma does not qualify
- Be well enough to do daily activities (ECOG 0 or 1) and expect to live at least 3 months
- Have measurable tumors on scans and enough healthy organ function based on recent blood/organ tests
- Have tumor tissue or cells available for genetic testing (NGS) or have an acceptable test result
- If you can get pregnant: have a negative pregnancy test and agree to strict birth control during the study and for 1 year after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for advanced melanoma that can be surgically removed. It combines your own immune cells (called gamma-delta T cells) with a drug (interferon or a PD-1 blocker) to see if it helps the body fight the cancer before and after surgery.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.